Education
About Us
Working with TipRanks
Follow Us
Innovation Pharmaceuticals Inc (IPIX)
OTHER OTC:IPIX
Total Valuation
Innovation Pharmaceuticals has a market cap or net worth of $161.18K. The enterprise value is -$1.20M.
Market Cap$161.18K
Enterprise Value-$1.20M
Share Statistics
Innovation Pharmaceuticals has 532,947,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding532,947,450
Owned by Insiders―
Owned by Institutions0.01%
Financial Efficiency
Innovation Pharmaceuticals’s return on equity (ROE) is -1.55 and return on invested capital (ROIC) is -112.55%.
Return on Equity (ROE)-1.55
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-112.55%
Return on Capital Employed (ROCE)-1.25
Revenue Per Employee0.00
Profits Per Employee-792.00K
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Innovation Pharmaceuticals is -3.19. Innovation Pharmaceuticals’s PEG ratio is ―.
PE Ratio-3.19
PS Ratio0.00
PB Ratio0.02
Price to Fair Value4.96
Price to FCF-0.02
Price to Operating Cash Flow-0.02
PEG Ratio―
Income Statement
In the last 12 months, Innovation Pharmaceuticals had revenue of 0.00 and earned -3.17M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-373.00K
Operating Income-3.11M
Pretax Income-3.17M
Net Income-3.17M
EBITDA-2.74M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.99M and capital expenditures -58.00K, giving a free cash flow of -2.05M billion.
Operating Cash Flow-1.99M
Free Cash Flow-2.05M
Free Cash Flow per Share>-0.01
Dividends & Yields
Innovation Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-2.64
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)233.53K
Important Dates
Innovation Pharmaceuticals upcoming earnings date is May 10, 2018, TBA Not Confirmed.
Last Earnings DateInvalid Date
Next Earnings DateMay 10, 2018
Ex-Dividend Date―
Financial Position
Innovation Pharmaceuticals as a current ratio of 0.33, with Debt / Equity ratio of 13.14%
Current Ratio0.33
Quick Ratio0.33
Debt to Market Cap0.07
Net Debt to EBITDA0.46
Interest Coverage Ratio-54.58
Taxes
In the past 12 months, Innovation Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Innovation Pharmaceuticals EV to EBITDA ratio is -3.24, with an EV/FCF ratio of -4.09.
EV to Sales0.00
EV to EBITDA-3.24
EV to Free Cash Flow-4.09
EV to Operating Cash Flow-4.21
Balance Sheet
Innovation Pharmaceuticals has $864.00K in cash and marketable securities with $238.00K in debt, giving a net cash position of -$626.00K billion.
Cash & Marketable Securities$864.00K
Total Debt$238.00K
Net Cash-$626.00K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Innovation Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―